Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's Macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH)

Leukemia Research

Volumn 34, Issue 10, 2010, Pages 1340-1343

  Kastritis, Efstathios ^a   Kyrtsonis, Marie Christine ^a   Hadjiharissi, Evdoxia ^a   Symeonidis, Argyris ^a   Michalis, Evridiki ^a   Repoussis, Panagiotis ^a   Tsatalas, Constantinos ^a   Michael, Michael ^a   Sioni, Anastasia ^a   Kartasis, Zafiris ^a   Stefanoudaki, Ekaterini ^a   Voulgarelis, Michail ^a   Delimpasi, Sossana ^a   Gavriatopoulou, Maria ^a   Koulieris, Efstathios ^a   Gika, Dimitra ^a   Zomas, Athanasios ^a   Roussou, Paraskevi ^a   Anagnostopoulos, Nikolaos ^a   Economopoulos, Theophanis ^a   Terpos, Evangelos ^a   Zervas, Konstantinos ^a   Dimopoulos, Meletios A ^a   more..

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Age; Cause specific survival; High risk; Lymphoplasmatic lymphoma; Prognosis

Indexed keywords

ALKYLATING AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE; NUCLEOSIDE ANALOG; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CAUSE SPECIFIC SURVIVAL; CONTROLLED STUDY; HIGH RISK PATIENT; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; VALIDATION STUDY; WALDENSTROEM MACROGLOBULINEMIA;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; L-LACTATE DEHYDROGENASE; MIDDLE AGED; PROGNOSIS; WALDENSTROM MACROGLOBULINEMIA;

EID: 77956249852     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.04.005     Document Type: Article

References (24)

1. Owen R.G., Treon S.P., Al-Katib A., Fonseca R., Greipp P.R., McMaster M.L., et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003, 30(April (2)):110-115.
2. Dimopoulos M.A., Kyle R.A., Anagnostopoulos A., Treon S.P. Diagnosis and management of Waldenstrom's macroglobulinemia. J Clin Oncol 2005, 23(March (7)):1564-1577.
3. Treon S.P., Gertz M.A., Dimopoulos M., Anagnostopoulos A., Blade J., Branagan A.R., et al. Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Blood 2006, 107(May (9)):3442-3446.
4. Ghobrial I.M., Fonseca R., Gertz M.A., Plevak M.F., Larson D.R., Therneau T.M., et al. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol 2006, 133(April (2)):158-164.
5. Merlini G., Baldini L., Broglia C., Comelli M., Goldaniga M., Palladini G., et al. Prognostic factors in symptomatic Waldenstrom's macroglobulinemia. Semin Oncol 2003, 30(April (2)):211-215.
6. Anagnostopoulos A., Zervas K., Kyrtsonis M., Symeonidis A., Gika D., Bourantas K., et al. Prognostic value of serum beta2-microglobulin in patients with Waldenstrom's macroglobulinemia requiring treatment. Clin Lymphoma Myeloma 2006, 7(November (3)):205-209.
7. Dhodapkar M.V., Jacobson J.L., Gertz M.A., Crowley J.J., Barlogie B. Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US intergroup trial (SW0G S9003). Semin Oncol 2003, 30(April (2)):220-225.
8. Facon T., Brouillard M., Duhamel A., Morel P., Simon M., Jouet J.P., et al. Prognostic factors in Waldenstrom's macroglobulinemia: a report of 167 cases. J Clin Oncol 1993, 11(August (8)):1553-1558.
9. Gobbi P.G., Bettini R., Montecucco C., Cavanna L., Morandi S., Pieresca C., et al. Study of prognosis in Waldenstrom's macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utility. Blood 1994, 83(May (10)):2939-2945.
10. Kyrtsonis M.C., Vassilakopoulos T.P., Angelopoulou M.K., Siakantaris P., Kontopidou F.N., Dimopoulou M.N., et al. Waldenstrom's macroglobulinemia: clinical course and prognostic factors in 60 patients. Experience from a single hematology unit. Ann Hematol 2001, 80(December (12)):722-727.
11. Morel P., Monconduit M., Jacomy D., Lenain P., Grosbois B., Bateli C., et al. patients with the description of a new scoring system and its validation on 253 other patients. Blood 2000, 96(August (3)):852-858.
12. Owen R.G., Barrans S.L., Richards S.J., O'Connor S.J., Child J.A., Parapia L.A., et al. Waldenstrom macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors. Am J Clin Pathol 2001, 116(September (3)):420-428.
13. Stalnikiewicz L., Carrotte-Lefebvre I., Detourmignies L., Rose C., Cazin B., Leblond V., et al. Prognostic factors in Waldenstrom's macroglobulinemia: description of the complications during the evolution-preliminary results on 101 patients. Semin Oncol 2003, 30(April (2)):216-219.
14. Morel P., Duhamel A., Gobbi P., Dimopoulos M.A., Dhodapkar M.V., McCoy J., et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 2009, 113(April (18)):4163-4170.
15. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. New Engl J Med 1993, 329(September (14)):987-994.
16. Solal-Celigny P., Roy P., Colombat P., White J., Armitage J.O., Arranz-Saez R., et al. Follicular lymphoma international prognostic index. Blood 2004, 104(September (5)):1258-1265.
17. Hoster E., Dreyling M., Klapper W., Gisselbrecht C., van Hoof A., Kluin-Nelemans H.C., et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008, 111(January (2)):558-565.
18. Dimopoulos M.A., Barlogie B., Smith T.L., Alexanian R. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med 1991, 115(December (12)):931-935.
19. Kyle R.A., Treon S.P., Alexanian R., Barlogie B., Bjorkholm M., Dhodapkar M., et al. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003, 30(April (2)):116-120.
20. Hasenclever D., Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. New Engl J Med 1998, 339(November (21)):1506-1514.
21. Lossos I.S., Czerwinski D.K., Alizadeh A.A., Wechser M.A., Tibshirani R., Botstein D., et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. New Engl J Med 2004, 350(April (18)):1828-1837.
22. Kastritis E., Zervas K., Repoussis P., Michali E., Katodrytou E., Zomas A., et al. Prognostication in young and old patients with Waldenstrom's macroglobulinemia: importance of the International Prognostic Scoring System and of serum lactate dehydrogenase. Clin Lymphoma Myeloma 2009, 9(March (1)):50-52.
23. Hoering A., Crowley J., Shaughnessy J.D., Hollmig K., Alsayed Y., Szymonifka J., et al. Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in total therapy protocols. Blood 2009, 114(August (7)):1299-1305.
24. Dimopoulos M.A., Kastritis E., Delimpassi S., Zomas A., Kyrtsonis M.C., Zervas K. The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens. Haematologica 2008, 93(September (9)):1420-1422.